SlideShare a Scribd company logo
1 of 1
Download to read offline
Expert Recommendations for the Laboratory Diagnosis of
Neuronal Ceroid Lipofuscinosis Type 2 (CLN2 disease): Diagnostic Algorithm
and Best Practice Guidelines for a Timely Diagnosis
Michael Fietz1*
, Roberto Giugliani2*
, Moeenaldeen AlSayed3
, Derek Burke4
, Jessica Cohen-Pfeffer5
, Jonathan D Cooper6
, Ines Noher de Halac7
, Lenka Dvořáková8
, Emanuela Izzo5
, Helena Jahnová8
, Zoltan Lukacs9
, Sara E. Mole10
,
David A. Pearce11
, Angela Schulz12
, Nicola Specchio13
, Winnie Xin14
, and Nicole Miller5
* Co- first authors
1
Department of Diagnostic Genomics, PathWest Laboratory Medicine WA, Nedlands, Australia, 2
Serviço de Genética Médica Hospital de Clinicas de Porto Alegre, Departamento de Genética Universidade Federal do Rio Grande do Sul and National Institute of Medical Genetics Population, Porto Alegre, Rio Grande do Sul, Brazil,
3
Department of Medical Genetics, Alfaisal University and King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia, 4
Chemical Pathology, Camelia Botnar Laboratories, Great Ormond Street Hospital, London, UK, 5
BioMarin Pharmaceutical Inc., Novato, California, USA, 6
Institute of Psychiatry, Psychology, & Neuroscience, King’s College London, London, UK,
7
Facultad de Ciencias Médicas, Universidad Nacional de Córdoba, Córdoba, Argentina and National Research Council-CONICET, Argentina, 8
Institute of Inherited Metabolic Disorders, First Faculty of Medicine, Charles University in Prague and General University Hospital in Prague, Prague, Czech Republic,
9
Newborn screening and Metabolic Diagnostics unit, Hamburg University Medical Center, Hamburg, Germany, 10
MRC Laboratory for Molecular Cell Biology and UCL Institute of Child Health, University College London, London, UK, 11
Sanford Children’s Health Research Center, Sioux Falls, South Dakota, USA,
12
Children’s Hospital, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, 13
Department of Neuroscience, Bambino Gesù Children’s Hospital, Rome, Italy, 14Neurogenetics DNA Diagnostic Lab, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA
ABSTRACT
The neuronal ceroid lipofuscinoses (NCLs) are a heterogeneous group of lysosomal storage disorders
that include the rare autosomal recessive neurodegenerative disorder, CLN2 disease. CLN2 disease is
caused by mutations in the TPP1/CLN2 gene, resulting in tripeptidyl peptidase-1 (TPP1) enzyme
deficiency. Classic late-infantile CLN2 disease phenotype has a pediatric onset with initial symptoms
of language delay and seizures, followed by progressive dementia, motor and visual deterioration, and
early death. Variant phenotypes of CLN2 disease occur more rarely. Diagnosis of CLN2 disease is
based on laboratory testing following clinical suspicion; however, delays in diagnosis are common due
to low disease awareness, non-specific initial symptoms, and limited diagnostic testing access in some
regions. With the advent of new therapies, early CLN2 disease diagnosis is key to ensure optimal clinical
care and outcomes.
In May 2015, a panel of international experts met to recommend best laboratory practices for early
diagnosis of CLN2 disease. When NCL is suspected due to the presence of suggestive clinical signs,
a TPP1 enzyme activity test should be the first diagnostic test performed (along with palmitoyl protein
thioesterase [PPT1] enzyme to exclude CLN1). However, since initial suspicion of CLN2 disease and
NCLs is often challenging, where available, the use of epilepsy gene panels for the investigation of
unexplained seizures in childhood is endorsed. These panels should include TPP1/CLN2 as well as
genes for NCLs that lack diagnostic biochemical tests.
Diagnostic TPP1 enzyme testing in leucocytes is well established and robust and in DBS is considered
diagnostic if followed by molecular confirmatory testing. Future methods to measure TPP1 activity via
tandem mass spectrometry may improve DBS-based TPP1 enzyme testing sensitivity. Experts recommend
that to confirm specific clinical suspicion of CLN2 disease, the gold standard for laboratory diagnosis is
demonstrating deficient TPP1 enzyme activity and/or detecting causative mutations in each allele of the
TPP1/CLN2 gene.
Addendum: After abstract submission, the gold standard statement was revised to the following
to reflect a more clear recommendation for laboratory diagnosis: “The gold standard for laboratory
diagnosis is demonstrating deficient TPP1 enzyme activity and detecting causative mutations in
each allele of the TPP1/CLN2 gene.”
BACKGROUND
■■ Since early symptoms of CLN2 disease are not specific, prior to ordering specific laboratory tests for
diagnosis of CLN2 disease, there are 3 (often sequential) phases through which many clinicians will
pass: (1) suspicion of an unknown neurological disorder, (2) general suspicion of an NCL disorder, and
finally, (3) specific suspicion of CLN2 disease.
–– Diagnosis of CLN2 often involves lengthy diagnostic odysseys (Figure 1).
Figure 1. Typical CLN2 Disease Diagnostic Odyssey
1- to 4-year delay
Further symptom progression:
seizures, language loss,
developmental milestone loss,
visual deterioration, others
Symptoms progress:
eizures, motor symptoms,
developmental milestone
regression, others
Early symptoms:
unexplained new onset
seizures
Clinical observations
Onset of symptoms
Specific confirmatory lab tests:
TPP1 enzyme activity defect and
gene mutations
Diagnostic investigations:
clinical tests, generic EEG,
MRI, etc
Epilepsy or developmental
delay gene panels
NCL gene panels,
enzyme activity
or electron microscopy
EEG photic stimulation
-
s
panels,
light
TPP1/CLN2
Unknown neurological disorder
Is it linked to a genetic disorder?
Clinical/laboratory tests
Low suspicion
High suspicion
CLN2
disease
Neuronal ceroid
lipofuscinosis
The above is a description of typical diagnostic practice. The specific tests ordered, approaches and techniques may vary among different
laboratories, clinicians and centers worldwide depending on local diagnostic testing availability and disease awareness.
Figure 2. Typical Delays in the Diagnosis of CLN2 Disease
Results from survey of NCL clinical experts (N = 12) responding to the question, From your own
experience, for patients not initially seen by NCL specialists, what is the time from onset of CLN2
disease symptoms until:
0 10 20 30 40 50
Months from onset of CLN2 symptoms until:
1 year: 82%
1 year: 100%
From left to right: minimum, mean, maximum
Referral to an
NCL specialist
Diagnosis with
CLN2 disease
■■ Delays in CLN2 disease diagnosis are common, but diagnosis is rapid once patients are referred to
appropriate specialists.
METHODS
■■ International NCL experts met in May 2015 to discuss and recommend best laboratory practices to
support early diagnosis of CLN2 disease.
■■ The algorithms and recommendations here reflect the consensus of the experts.
■■ TPP1 enzyme activities are reported as observed by individual diagnostic laboratories in samples
from unaffected individuals, heterozygous carriers, and individuals with CLN2 disease. Laboratories
utilized modifications of the fluorogenic TPP1 assay.1-6
The data presented here are not generated
from BioMarin-sponsored clinical trial patient samples.
APPROACH TO SUSPICION AND DIAGNOSIS
■■ Any unexplained seizure in a child 1 to 9 years of age,7
particularly when associated with a history
of language delay and/or developmental milestone regression, should be suspected as linked to a
genetic disorder or to an NCL disorder.
–– Atypical forms with alternative presentations exist, eg, juvenile forms and autosomal recessive
spinocerebellar ataxia 7 (SCAR7 disease, also caused by mutations in the TPP1/CLN2 gene).8
■■ When a genetic neurological disorder is suspected, a molecular gene panel test to investigate genetic
causes of childhood-onset epilepsy or developmental delay is recommended.
–– Experts recommend that the TPP1/CLN2 gene should be included in such gene panels.
■■ When NCL disorders in general are suspected, targeted NCL gene panels may help in reaching a
diagnosis of CLN2 disease, as well as other types of NCLs.
■■ EEG analysis under specific intermittent photic stimulation (1 to 2 Hz) may be of use as a clinical test
to reach a suspicion of CLN2 disease.9-11
–– EEG spikes in the posterior region in response to photic stimulation at 1-2 Hz are characteristic of
CLN2 disease and some other late-infantile NCLs (eg, CLN6 and CLN8 diseases).
■■ Early testing of TPP1 and PPT1 enzyme deficiency can rapidly rule out or confirm suspicion of CLN2
or CLN1 disease, respectively.
–– Assays for TPP1 and PPT1 enzyme activity are widely available.
–– CLN2 and CLN1 disease are the most prevalent NCL disorders among the late infantile NCL types.10
–– Enzyme activity assay exists also for cathepsin D (CLN10 disease), but routine laboratory testing
for this enzyme is currently less common.
Figure 3. Algorithm for Suspicion and Diagnosis of CLN2 Disease
Suspicion of a
genetic disorder
Suspicion of an
NCL disorder
Observation of common initial symptoms at
late-infantile age (2 to 4 years; classic phenotype)
or at juvenile age (> 4 years; atypical phenotype):
• New-onset seizures, in association with
• A history of language delay and/or
developmental milestone regression
Intermittent photic stimulation (1 to 2 Hz)
or screening of TPP1 and PPT1 enzymesa
Disease or symptom gene panelb
or
screening of TPP1 and PPT1 enzymesa
NCL gene panelb
or
screening of TPP1 and PPT1 enzymesa
TPP1 enzyme activity analysis
Leukocytes or fibroblasts or DBSc
Molecular analysis of the TPP1/CLN2 geneb
Diagnosis
Suspicion
Clinical testing and
differential diagnosis
Suspicion of
CLN2 disease
Laboratory confirmatory
diagnosis of CLN2 disease
CLN2 disease diagnosis
DBS, dried blood spot.
a
Early screening of TPP1 and PPT1 deficiency (eg, in DBS) can rule out or confirm CLN2 suspicion.
b
Molecular testing alone may be diagnostic if 2 pathogenic mutations consistent with clinical presentation are detected in trans.
c
A finding of deficient TPP1 enzyme activity in leukocytes or fibroblasts may be considered diagnostic if consistent with clinical presentation,
but molecular analysis is recommended.
■■ Following clinical suspicion, diagnosis of CLN2 disease is based on specific well-established
laboratory tests.
■■ TPP1 enzyme activity can be assessed in several sample types.
■■ Molecular analysis of the TPP1/CLN2 gene can confirm a diagnosis and assist genetic counseling.
The gold standard for diagnosis of CLN2 disease is:
■■ Demonstration of decreased or deficient TPP1 enzyme activity (together with normal activity
of appropriate controls); and
■■ Detection of 1 deleterious mutation in each allele of the TPP1/CLN2 gene
■■ If it is not possible to perform both the TPP1 enzyme assay and molecular testing due to
local restrictions:
–– A finding of deficient TPP1 enzyme activity in leukocytes or fibroblasts is diagnostic when
consistent with the clinical presentation of CLN2 disease.
–– Detection of two pathogenic TPP1/CLN2 mutations in trans is diagnostic in the absence of TPP1
enzyme testing results when consistent with clinical presentation.
RECOMMENDATIONS FOR LABORATORY DIAGNOSIS
Analysis of TPP1 Enzyme Activity
■■ The TPP1 enzyme is a lysosomal exopeptidase that cleaves N-terminal tripeptides.1-3,12
■■ Diagnostic laboratory assessment of TPP1 enzyme activity utilizes the fluorogenic substrate
Ala-Ala-Phe-7-amido-4-methylcoumarin.2,3,12
–– A substrate for assessment of TPP1 enzyme activity by tandem mass spectrometry has been
developed13
and may support future screening of newborn DBS samples.
143
■■ Several variants on the fluorogenic TPP1 enzyme assay have been published.4-6
■■ It is essential to assay the activity of control enzymes.
–– PPT1 (mutated in CLN1 disease) and β-galactosidase are appropriate control enzymes.
Figure 4. TPP1 Enzyme Activity in Leukocyte Samples, by Diagnostic Laboratory
1
2
3
4
5
0 100 200
Patient with CLN2 disease
Laboratory
TPP1 Enzyme Activity,
nmol/h/mg protein
Carrier Unaffected individuals
300 400
■■ Different assay implementations can distinguish affected from unaffected individuals.
–– Laboratories must establish reference ranges for their individual implementation.
Molecular Analysis of the TPP1/CLN2 Gene
■■ Mutations have been reported throughout the TPP1/CLN2 gene.14
■■ Two deleterious mutations are frequently reported: c.509-1GC and c.622CT (p.Arg208*).
–– These two mutations together represent 57% of all reported mutations.
–– At least 1 of these 2 mutations is reported in 89% of patients with CLN2 disease.14
■■ Sequencing should evaluate the entire coding region and associated splice junctions.
■■ A database of mutations associated with the TPP1/CLN2 gene, and other NCL genes, is maintained
at http://www.ucl.ac.uk/ncl/mutation.
Figure 5. Reported Frequency of TPP1/CLN2 Mutant Alleles14
c.509-1GC 156
p.Arg208* 149
At least 1 reported in
89% of patients
Missense
Splice site
Nonsense/stop
p.Gly284Val
p.Gln509*
p.Gln422His
35
18
10
176
0 25 50 75 100
Mutation Reported in Kousi et al, 2012
125 150 175 200
84 mutations reported  10 times
CONCLUSIONS
■■ CLN2 disease is a rare, progressive, and devastating disease that can be difficult to identify
clinically at an early stage.
–– Key initial symptoms in many patients are new-onset seizures, often in combination with
a history of early language delay.
–– Atypical forms of disease—with alternative presentations—caused by mutations in the
TPP1/CLN2 gene also exist, such as SCAR7.8
■■ Delays in diagnosis are common due to the time necessary to come to suspicion of CLN2
disease. Valuable tools to help speed time to diagnosis include:
–– EEG intermittent photic stimulation (1 to 2 Hz).
–– Symptom- or disease-based gene panels that include the TPP1/CLN2 gene.
–– Early screening for TPP1 enzyme deficiency (together with PPT1 for CLN1).
■■ Diagnostic laboratory testing for CLN2 disease is well established.
■■ The gold standard for laboratory diagnosis is demonstration of deficient TPP1 enzyme
activity and molecular analysis that detects 1 pathogenic mutation on each allele of
TPP1/CLN2 gene.
REFERENCES
1. Sohar I, et al. J Neurochem. 1999;73:700-711.
2. Vines D, Warburton MJ. Biochim Biophys Acta. 1998;1384:233-242.
3. Vines D, Warburton MJ. FEBS Lett. 1999;443:131-135.
4. Muller VJ, et al. Eur J Paediatr Neurol. 2001;5(suppl A):197-200.
5. Young EP, et al. Prenat Diagn. 2000;20:337-339.
6. Van Diggelen OP et al. Eur J Paediatr Neurol. 2001;5(suppl A):189-200.
7. Kohan R et al. Biochim Biophys Acta. 2013;1852:2301-2311.
8. Sun Y et al. Hum Mutat. 2013;34:706-713.
9. Binelli S, et al. Neurol Sci. 2000;21:S83-S87.
10. Mole SE, et al. The Neuronal Ceroid Lipofuscinoses (Batten disease). 2nd
edition. Oxford, UK: Oxford University Press; 2011.
11. Naqvi SZ, et al. Pediatr Neurol. 1998;19:395-398.
12. Sleat DE, et al. Science. 1997;277:1802-1805.
13. Barcenas M, et al. Anal Chem. 2014;86:7962-7968.
14. Kousi M, et al. Hum Mutat. 2012;33:42-63.
ACKNOWLEDGMENTS
The authors thank Karl Zawadzki, PhD,
and Evelyn Rose, PharmD (Health Interactions),
for assistance with the preparation of this poster,
which was funded by BioMarin Pharmaceutical Inc.
©2016 BioMarin Pharmaceutical Inc. All rights reserved.Presented at the 12th Annual WORLD Symposium: 29 February – 4 March, 2016, San Diego, CA
http://www.biomarin.com/pdf/WORLD2016p7.pdf

More Related Content

What's hot

Martin duddy, drugs on the horizon
Martin duddy, drugs on the horizonMartin duddy, drugs on the horizon
Martin duddy, drugs on the horizonMS Trust
 
The Role of DaT Scan in Diagnosing Parkinson Disease
The Role of DaT Scan in Diagnosing Parkinson Disease The Role of DaT Scan in Diagnosing Parkinson Disease
The Role of DaT Scan in Diagnosing Parkinson Disease Ade Wijaya
 
Dr Trevor Pickersgill - Diagnosing a Relapse
Dr Trevor Pickersgill - Diagnosing a RelapseDr Trevor Pickersgill - Diagnosing a Relapse
Dr Trevor Pickersgill - Diagnosing a RelapseMS Trust
 
Dr. kristen park kcnq2 Cure summit parent track learn more at kcnq2cure.org
Dr. kristen park kcnq2 Cure summit parent track learn more at kcnq2cure.orgDr. kristen park kcnq2 Cure summit parent track learn more at kcnq2cure.org
Dr. kristen park kcnq2 Cure summit parent track learn more at kcnq2cure.orgscottyandjim
 
Precision medicine seminar....2017
Precision medicine seminar....2017Precision medicine seminar....2017
Precision medicine seminar....2017nirmalk1503
 
The new treatment paradigm for MS
The new treatment paradigm for MSThe new treatment paradigm for MS
The new treatment paradigm for MSMS Trust
 
Chronic Neuroinflammation in Alzheimer’s Disease New Perspectives Animal Mode...
Chronic Neuroinflammation in Alzheimer’s Disease New Perspectives Animal Mode...Chronic Neuroinflammation in Alzheimer’s Disease New Perspectives Animal Mode...
Chronic Neuroinflammation in Alzheimer’s Disease New Perspectives Animal Mode...Niloo Karunaweera
 
A Comprehensive Comparison Research Paper
A Comprehensive Comparison Research PaperA Comprehensive Comparison Research Paper
A Comprehensive Comparison Research PaperJennifer Ocasio
 
Delirium in ICU: Nomenclature and Diagnosis
Delirium in ICU: Nomenclature and DiagnosisDelirium in ICU: Nomenclature and Diagnosis
Delirium in ICU: Nomenclature and DiagnosisSimone Piva
 
04 saturday post lunch track 2 10-25-14
04 saturday post lunch   track 2 10-25-1404 saturday post lunch   track 2 10-25-14
04 saturday post lunch track 2 10-25-14LGS Foundation
 
Stanislav Zakharenko: Studying Psychosis in 22q11 Deletion Syndrome
Stanislav Zakharenko: Studying Psychosis in 22q11 Deletion SyndromeStanislav Zakharenko: Studying Psychosis in 22q11 Deletion Syndrome
Stanislav Zakharenko: Studying Psychosis in 22q11 Deletion Syndromewef
 
Definition and natural history of Lennox Gastaut syndrome
Definition and natural history of Lennox Gastaut syndromeDefinition and natural history of Lennox Gastaut syndrome
Definition and natural history of Lennox Gastaut syndromePramod Krishnan
 
Neuropsychiatric consequences of traumatic brain injury
Neuropsychiatric consequences of traumatic brain injuryNeuropsychiatric consequences of traumatic brain injury
Neuropsychiatric consequences of traumatic brain injuryDikshya upreti
 
LGS Foundation 2016 Conference - Saturday Morning
LGS Foundation 2016 Conference - Saturday MorningLGS Foundation 2016 Conference - Saturday Morning
LGS Foundation 2016 Conference - Saturday MorningLGS Foundation
 
Trials in secondary progressive multiple sclerosis: design & efficiency
Trials in secondary progressive multiple sclerosis: design & efficiencyTrials in secondary progressive multiple sclerosis: design & efficiency
Trials in secondary progressive multiple sclerosis: design & efficiencyMS Trust
 
Multiple sclerosis
Multiple sclerosisMultiple sclerosis
Multiple sclerosisAditya Singh
 
Anne Bassett: Studying Psychosis in 22q11 Deletion Syndrome
Anne Bassett:  Studying Psychosis in 22q11 Deletion SyndromeAnne Bassett:  Studying Psychosis in 22q11 Deletion Syndrome
Anne Bassett: Studying Psychosis in 22q11 Deletion Syndromewef
 

What's hot (20)

Martin duddy, drugs on the horizon
Martin duddy, drugs on the horizonMartin duddy, drugs on the horizon
Martin duddy, drugs on the horizon
 
The Role of DaT Scan in Diagnosing Parkinson Disease
The Role of DaT Scan in Diagnosing Parkinson Disease The Role of DaT Scan in Diagnosing Parkinson Disease
The Role of DaT Scan in Diagnosing Parkinson Disease
 
2018 BDSRA Gayko
2018 BDSRA Gayko2018 BDSRA Gayko
2018 BDSRA Gayko
 
Dr Trevor Pickersgill - Diagnosing a Relapse
Dr Trevor Pickersgill - Diagnosing a RelapseDr Trevor Pickersgill - Diagnosing a Relapse
Dr Trevor Pickersgill - Diagnosing a Relapse
 
Dr. kristen park kcnq2 Cure summit parent track learn more at kcnq2cure.org
Dr. kristen park kcnq2 Cure summit parent track learn more at kcnq2cure.orgDr. kristen park kcnq2 Cure summit parent track learn more at kcnq2cure.org
Dr. kristen park kcnq2 Cure summit parent track learn more at kcnq2cure.org
 
Precision medicine seminar....2017
Precision medicine seminar....2017Precision medicine seminar....2017
Precision medicine seminar....2017
 
The new treatment paradigm for MS
The new treatment paradigm for MSThe new treatment paradigm for MS
The new treatment paradigm for MS
 
Chronic Neuroinflammation in Alzheimer’s Disease New Perspectives Animal Mode...
Chronic Neuroinflammation in Alzheimer’s Disease New Perspectives Animal Mode...Chronic Neuroinflammation in Alzheimer’s Disease New Perspectives Animal Mode...
Chronic Neuroinflammation in Alzheimer’s Disease New Perspectives Animal Mode...
 
A Comprehensive Comparison Research Paper
A Comprehensive Comparison Research PaperA Comprehensive Comparison Research Paper
A Comprehensive Comparison Research Paper
 
2016 BDSRA Whiting & Katz CLN2
2016 BDSRA Whiting & Katz CLN22016 BDSRA Whiting & Katz CLN2
2016 BDSRA Whiting & Katz CLN2
 
Delirium in ICU: Nomenclature and Diagnosis
Delirium in ICU: Nomenclature and DiagnosisDelirium in ICU: Nomenclature and Diagnosis
Delirium in ICU: Nomenclature and Diagnosis
 
04 saturday post lunch track 2 10-25-14
04 saturday post lunch   track 2 10-25-1404 saturday post lunch   track 2 10-25-14
04 saturday post lunch track 2 10-25-14
 
Stanislav Zakharenko: Studying Psychosis in 22q11 Deletion Syndrome
Stanislav Zakharenko: Studying Psychosis in 22q11 Deletion SyndromeStanislav Zakharenko: Studying Psychosis in 22q11 Deletion Syndrome
Stanislav Zakharenko: Studying Psychosis in 22q11 Deletion Syndrome
 
Definition and natural history of Lennox Gastaut syndrome
Definition and natural history of Lennox Gastaut syndromeDefinition and natural history of Lennox Gastaut syndrome
Definition and natural history of Lennox Gastaut syndrome
 
Neuropsychiatric consequences of traumatic brain injury
Neuropsychiatric consequences of traumatic brain injuryNeuropsychiatric consequences of traumatic brain injury
Neuropsychiatric consequences of traumatic brain injury
 
LGS Foundation 2016 Conference - Saturday Morning
LGS Foundation 2016 Conference - Saturday MorningLGS Foundation 2016 Conference - Saturday Morning
LGS Foundation 2016 Conference - Saturday Morning
 
Trials in secondary progressive multiple sclerosis: design & efficiency
Trials in secondary progressive multiple sclerosis: design & efficiencyTrials in secondary progressive multiple sclerosis: design & efficiency
Trials in secondary progressive multiple sclerosis: design & efficiency
 
Multiple sclerosis
Multiple sclerosisMultiple sclerosis
Multiple sclerosis
 
Anne Bassett: Studying Psychosis in 22q11 Deletion Syndrome
Anne Bassett:  Studying Psychosis in 22q11 Deletion SyndromeAnne Bassett:  Studying Psychosis in 22q11 Deletion Syndrome
Anne Bassett: Studying Psychosis in 22q11 Deletion Syndrome
 
Robbins Alzheimers Dementia Toma 2006
Robbins Alzheimers Dementia Toma 2006Robbins Alzheimers Dementia Toma 2006
Robbins Alzheimers Dementia Toma 2006
 

Viewers also liked

Viewers also liked (17)

2014 BDSRA Cooper JNCL
2014 BDSRA Cooper JNCL2014 BDSRA Cooper JNCL
2014 BDSRA Cooper JNCL
 
BDSRA 2015 CLN1 Hofmann
BDSRA 2015 CLN1 HofmannBDSRA 2015 CLN1 Hofmann
BDSRA 2015 CLN1 Hofmann
 
2014 BDSRA Palmer CLN 5 and CLN 6
2014 BDSRA Palmer CLN 5 and CLN 62014 BDSRA Palmer CLN 5 and CLN 6
2014 BDSRA Palmer CLN 5 and CLN 6
 
2016 BDSRA Mole CLN1, CLN2, CLN3, CLN5, CLN6, CLN7,
2016 BDSRA Mole CLN1, CLN2, CLN3, CLN5, CLN6, CLN7,2016 BDSRA Mole CLN1, CLN2, CLN3, CLN5, CLN6, CLN7,
2016 BDSRA Mole CLN1, CLN2, CLN3, CLN5, CLN6, CLN7,
 
2014 BDSRA Berkovic Adult NCL
2014 BDSRA Berkovic Adult NCL2014 BDSRA Berkovic Adult NCL
2014 BDSRA Berkovic Adult NCL
 
BDSRA 2015 CLN1 CLN2 CLN3 Sleat, Lobel
BDSRA 2015 CLN1 CLN2 CLN3 Sleat, Lobel BDSRA 2015 CLN1 CLN2 CLN3 Sleat, Lobel
BDSRA 2015 CLN1 CLN2 CLN3 Sleat, Lobel
 
CLN8 Pesaola 2013
CLN8 Pesaola 2013CLN8 Pesaola 2013
CLN8 Pesaola 2013
 
2012 ANCL Smith, Dahl, Damiano. Bahlo &Berkovic
2012 ANCL Smith, Dahl, Damiano. Bahlo &Berkovic2012 ANCL Smith, Dahl, Damiano. Bahlo &Berkovic
2012 ANCL Smith, Dahl, Damiano. Bahlo &Berkovic
 
2012 CLN5 Boustany
2012 CLN5 Boustany2012 CLN5 Boustany
2012 CLN5 Boustany
 
BDSRA 2015 Gene Therapy for the Eye, Mole
BDSRA 2015 Gene Therapy for the Eye, MoleBDSRA 2015 Gene Therapy for the Eye, Mole
BDSRA 2015 Gene Therapy for the Eye, Mole
 
BDSRA 2015 CLN6 Mole
BDSRA 2015 CLN6 MoleBDSRA 2015 CLN6 Mole
BDSRA 2015 CLN6 Mole
 
BDSRA 2015 CLN3 Kielian
BDSRA 2015 CLN3 KielianBDSRA 2015 CLN3 Kielian
BDSRA 2015 CLN3 Kielian
 
2016 BDSRA Cotman, Chandrachud, Hillje, Ilo, Nowell, Oh CLN2, CLN3, CLN6, Adu...
2016 BDSRA Cotman, Chandrachud, Hillje, Ilo, Nowell, Oh CLN2, CLN3, CLN6, Adu...2016 BDSRA Cotman, Chandrachud, Hillje, Ilo, Nowell, Oh CLN2, CLN3, CLN6, Adu...
2016 BDSRA Cotman, Chandrachud, Hillje, Ilo, Nowell, Oh CLN2, CLN3, CLN6, Adu...
 
2013 Vlincl lehesjoki
2013 Vlincl lehesjoki2013 Vlincl lehesjoki
2013 Vlincl lehesjoki
 
2016 BDSRA Cooper CLN1, CLN2, CLN3, CLN5, CLN6, CLN7
2016 BDSRA Cooper CLN1, CLN2, CLN3, CLN5, CLN6, CLN72016 BDSRA Cooper CLN1, CLN2, CLN3, CLN5, CLN6, CLN7
2016 BDSRA Cooper CLN1, CLN2, CLN3, CLN5, CLN6, CLN7
 
2016 BDSRA Shyng, Nelvagal, Dearborn, Cooper, Sands CLN1
2016 BDSRA Shyng, Nelvagal, Dearborn, Cooper, Sands CLN12016 BDSRA Shyng, Nelvagal, Dearborn, Cooper, Sands CLN1
2016 BDSRA Shyng, Nelvagal, Dearborn, Cooper, Sands CLN1
 
2013 ANCL Mole
2013 ANCL Mole2013 ANCL Mole
2013 ANCL Mole
 

Similar to 2016 BDSRA Fietz, Giugliani, AlSayed, Burke, Cohen-Pfeffer, Cooper, de Halec, Dvorakova, Izzo, Jahnova, Lukacs, Mole, Pearce, Schulz, Specchio, Xin, Miller

lipocaline.pdf
lipocaline.pdflipocaline.pdf
lipocaline.pdfhaneya2
 
lipocaline.pdf
lipocaline.pdflipocaline.pdf
lipocaline.pdfhaneya2
 
NLR (NEUTROPHIL LYMPHOCYTE RATIO).pptx
NLR (NEUTROPHIL LYMPHOCYTE RATIO).pptxNLR (NEUTROPHIL LYMPHOCYTE RATIO).pptx
NLR (NEUTROPHIL LYMPHOCYTE RATIO).pptxAasiaQureshi2
 
SYSTEMIC LUPUS ERYTHEMATOSUS PRESENTATION.pptx
SYSTEMIC LUPUS ERYTHEMATOSUS PRESENTATION.pptxSYSTEMIC LUPUS ERYTHEMATOSUS PRESENTATION.pptx
SYSTEMIC LUPUS ERYTHEMATOSUS PRESENTATION.pptxogadatv
 
Case presentation neurology
Case presentation neurologyCase presentation neurology
Case presentation neurologyDr. Armaan Singh
 
A case of Neuromyelitis optica as a presenting manifestation of Systemic Lupu...
A case of Neuromyelitis optica as a presenting manifestation of Systemic Lupu...A case of Neuromyelitis optica as a presenting manifestation of Systemic Lupu...
A case of Neuromyelitis optica as a presenting manifestation of Systemic Lupu...Apollo Hospitals
 
paraneopasticneurologicaldisorder-190123162155.pdf
paraneopasticneurologicaldisorder-190123162155.pdfparaneopasticneurologicaldisorder-190123162155.pdf
paraneopasticneurologicaldisorder-190123162155.pdfMahimaChuohan
 
Paraneopastic Neurological Disorder
Paraneopastic Neurological DisorderParaneopastic Neurological Disorder
Paraneopastic Neurological DisorderAhmad Shahir
 
04 saturday post lunch track 1 10-25-14
04 saturday post lunch   track 1 10-25-1404 saturday post lunch   track 1 10-25-14
04 saturday post lunch track 1 10-25-14LGS Foundation
 
Vetrugno, Exp Op Orph Drugs, 15
Vetrugno, Exp Op Orph Drugs, 15Vetrugno, Exp Op Orph Drugs, 15
Vetrugno, Exp Op Orph Drugs, 15Vito Vetrugno
 
Lab diagnosis of ctd By Dr Arif Iqbal MD Dermatology UCMS & GTBH
Lab diagnosis of ctd By Dr Arif Iqbal MD Dermatology UCMS & GTBHLab diagnosis of ctd By Dr Arif Iqbal MD Dermatology UCMS & GTBH
Lab diagnosis of ctd By Dr Arif Iqbal MD Dermatology UCMS & GTBH7867878678
 
Dr. sarah weckhuysen kcnq2 Cure summit professional track - Lean more at kcn...
Dr. sarah weckhuysen kcnq2 Cure summit professional track -  Lean more at kcn...Dr. sarah weckhuysen kcnq2 Cure summit professional track -  Lean more at kcn...
Dr. sarah weckhuysen kcnq2 Cure summit professional track - Lean more at kcn...scottyandjim
 
Biomarkers for Parkinson's Diseases
Biomarkers for Parkinson's DiseasesBiomarkers for Parkinson's Diseases
Biomarkers for Parkinson's DiseasesVivek Misra
 
Ns1 protien in dengue virus causing thrombocytopenia.
Ns1 protien in dengue virus causing thrombocytopenia.Ns1 protien in dengue virus causing thrombocytopenia.
Ns1 protien in dengue virus causing thrombocytopenia.Yalnaz1
 

Similar to 2016 BDSRA Fietz, Giugliani, AlSayed, Burke, Cohen-Pfeffer, Cooper, de Halec, Dvorakova, Izzo, Jahnova, Lukacs, Mole, Pearce, Schulz, Specchio, Xin, Miller (20)

2016 BDSRA Williams, Cohen-Pfeffer, Crystal, de los Reyes, Eto, Guelber, Hero...
2016 BDSRA Williams, Cohen-Pfeffer, Crystal, de los Reyes, Eto, Guelber, Hero...2016 BDSRA Williams, Cohen-Pfeffer, Crystal, de los Reyes, Eto, Guelber, Hero...
2016 BDSRA Williams, Cohen-Pfeffer, Crystal, de los Reyes, Eto, Guelber, Hero...
 
lipocaline.pdf
lipocaline.pdflipocaline.pdf
lipocaline.pdf
 
lipocaline.pdf
lipocaline.pdflipocaline.pdf
lipocaline.pdf
 
2014 BDSRA Davidson LINCL
2014 BDSRA Davidson LINCL2014 BDSRA Davidson LINCL
2014 BDSRA Davidson LINCL
 
2017 BDSRA Whiting and Katz CLN2
2017 BDSRA Whiting and Katz CLN22017 BDSRA Whiting and Katz CLN2
2017 BDSRA Whiting and Katz CLN2
 
NLR (NEUTROPHIL LYMPHOCYTE RATIO).pptx
NLR (NEUTROPHIL LYMPHOCYTE RATIO).pptxNLR (NEUTROPHIL LYMPHOCYTE RATIO).pptx
NLR (NEUTROPHIL LYMPHOCYTE RATIO).pptx
 
SYSTEMIC LUPUS ERYTHEMATOSUS PRESENTATION.pptx
SYSTEMIC LUPUS ERYTHEMATOSUS PRESENTATION.pptxSYSTEMIC LUPUS ERYTHEMATOSUS PRESENTATION.pptx
SYSTEMIC LUPUS ERYTHEMATOSUS PRESENTATION.pptx
 
Case presentation neurology
Case presentation neurologyCase presentation neurology
Case presentation neurology
 
Publication4
Publication4Publication4
Publication4
 
A case of Neuromyelitis optica as a presenting manifestation of Systemic Lupu...
A case of Neuromyelitis optica as a presenting manifestation of Systemic Lupu...A case of Neuromyelitis optica as a presenting manifestation of Systemic Lupu...
A case of Neuromyelitis optica as a presenting manifestation of Systemic Lupu...
 
paraneopasticneurologicaldisorder-190123162155.pdf
paraneopasticneurologicaldisorder-190123162155.pdfparaneopasticneurologicaldisorder-190123162155.pdf
paraneopasticneurologicaldisorder-190123162155.pdf
 
Paraneopastic Neurological Disorder
Paraneopastic Neurological DisorderParaneopastic Neurological Disorder
Paraneopastic Neurological Disorder
 
04 saturday post lunch track 1 10-25-14
04 saturday post lunch   track 1 10-25-1404 saturday post lunch   track 1 10-25-14
04 saturday post lunch track 1 10-25-14
 
Vetrugno, Exp Op Orph Drugs, 15
Vetrugno, Exp Op Orph Drugs, 15Vetrugno, Exp Op Orph Drugs, 15
Vetrugno, Exp Op Orph Drugs, 15
 
Lab diagnosis of ctd By Dr Arif Iqbal MD Dermatology UCMS & GTBH
Lab diagnosis of ctd By Dr Arif Iqbal MD Dermatology UCMS & GTBHLab diagnosis of ctd By Dr Arif Iqbal MD Dermatology UCMS & GTBH
Lab diagnosis of ctd By Dr Arif Iqbal MD Dermatology UCMS & GTBH
 
Dr. sarah weckhuysen kcnq2 Cure summit professional track - Lean more at kcn...
Dr. sarah weckhuysen kcnq2 Cure summit professional track -  Lean more at kcn...Dr. sarah weckhuysen kcnq2 Cure summit professional track -  Lean more at kcn...
Dr. sarah weckhuysen kcnq2 Cure summit professional track - Lean more at kcn...
 
Biomarkers for Parkinson's Diseases
Biomarkers for Parkinson's DiseasesBiomarkers for Parkinson's Diseases
Biomarkers for Parkinson's Diseases
 
Ns1 protien in dengue virus causing thrombocytopenia.
Ns1 protien in dengue virus causing thrombocytopenia.Ns1 protien in dengue virus causing thrombocytopenia.
Ns1 protien in dengue virus causing thrombocytopenia.
 
Ncomms5563
Ncomms5563Ncomms5563
Ncomms5563
 
Neurofilament light chain
Neurofilament light chainNeurofilament light chain
Neurofilament light chain
 

More from Batten Disease Support and Research Association

More from Batten Disease Support and Research Association (20)

2018 BDSRA Whiting CLN2
2018 BDSRA Whiting CLN22018 BDSRA Whiting CLN2
2018 BDSRA Whiting CLN2
 
2018 BDSRA Vierhile
2018 BDSRA Vierhile2018 BDSRA Vierhile
2018 BDSRA Vierhile
 
2018 BDSRA Storch CLN7
2018 BDSRA Storch CLN72018 BDSRA Storch CLN7
2018 BDSRA Storch CLN7
 
2018 BDSRA Gray CLN1
2018 BDSRA Gray CLN12018 BDSRA Gray CLN1
2018 BDSRA Gray CLN1
 
2018 BDSRA Hughes CLN6
2018 BDSRA Hughes CLN62018 BDSRA Hughes CLN6
2018 BDSRA Hughes CLN6
 
2018 BDSRA Roine CLN3
2018 BDSRA Roine CLN32018 BDSRA Roine CLN3
2018 BDSRA Roine CLN3
 
2018 BDSRA Roberge
2018 BDSRA Roberge 2018 BDSRA Roberge
2018 BDSRA Roberge
 
2018 BDSRA Circumvent Pharmaceuticals CLN1
2018 BDSRA Circumvent Pharmaceuticals CLN12018 BDSRA Circumvent Pharmaceuticals CLN1
2018 BDSRA Circumvent Pharmaceuticals CLN1
 
2018 BDSRA Cooper, Nelvagal
2018 BDSRA Cooper, Nelvagal2018 BDSRA Cooper, Nelvagal
2018 BDSRA Cooper, Nelvagal
 
2018 BDSRA Feuerborn
2018 BDSRA Feuerborn2018 BDSRA Feuerborn
2018 BDSRA Feuerborn
 
2018 BDSRA Cotman MGH Center for Genomic Medicine
2018 BDSRA Cotman MGH Center for Genomic Medicine2018 BDSRA Cotman MGH Center for Genomic Medicine
2018 BDSRA Cotman MGH Center for Genomic Medicine
 
2018 BDSRA Cotman CLN3
2018 BDSRA Cotman CLN32018 BDSRA Cotman CLN3
2018 BDSRA Cotman CLN3
 
2018 BDSRA Dang Do CLN3
2018 BDSRA Dang Do CLN32018 BDSRA Dang Do CLN3
2018 BDSRA Dang Do CLN3
 
2017 BDSRA Tammen, Grupen, James and Delerue CLN6 CLN7
2017 BDSRA Tammen, Grupen, James and Delerue CLN6 CLN72017 BDSRA Tammen, Grupen, James and Delerue CLN6 CLN7
2017 BDSRA Tammen, Grupen, James and Delerue CLN6 CLN7
 
2017 BDSRA Storch and Danyukova CLN7
2017 BDSRA Storch and Danyukova CLN72017 BDSRA Storch and Danyukova CLN7
2017 BDSRA Storch and Danyukova CLN7
 
2017 BDSRA Stehr and van der Putten, CLN3
2017 BDSRA Stehr and van der Putten, CLN32017 BDSRA Stehr and van der Putten, CLN3
2017 BDSRA Stehr and van der Putten, CLN3
 
2017 BDSRA Autti, U. Roine, T. Roine, Aberg, Tokola, Balk, Hakkarainen, Manne...
2017 BDSRA Autti, U. Roine, T. Roine, Aberg, Tokola, Balk, Hakkarainen, Manne...2017 BDSRA Autti, U. Roine, T. Roine, Aberg, Tokola, Balk, Hakkarainen, Manne...
2017 BDSRA Autti, U. Roine, T. Roine, Aberg, Tokola, Balk, Hakkarainen, Manne...
 
2017 BDSRA Trometer, Potier, Cournoyer, and Schermer
2017 BDSRA Trometer, Potier, Cournoyer, and Schermer2017 BDSRA Trometer, Potier, Cournoyer, and Schermer
2017 BDSRA Trometer, Potier, Cournoyer, and Schermer
 
2017 BDSRA Mole, Band, Codd and West CLN3, CLN6, CLN7
2017 BDSRA Mole, Band, Codd and West CLN3, CLN6, CLN72017 BDSRA Mole, Band, Codd and West CLN3, CLN6, CLN7
2017 BDSRA Mole, Band, Codd and West CLN3, CLN6, CLN7
 
2017 BDSRA Katz and Whiting All forms
2017 BDSRA Katz and Whiting All forms2017 BDSRA Katz and Whiting All forms
2017 BDSRA Katz and Whiting All forms
 

Recently uploaded

Adenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosisAdenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosisSujoy Dasgupta
 
Using Data Visualization in Public Health Communications
Using Data Visualization in Public Health CommunicationsUsing Data Visualization in Public Health Communications
Using Data Visualization in Public Health Communicationskatiequigley33
 
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdfSGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdfHongBiThi1
 
CPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing studentCPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing studentsaileshpanda05
 
AUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functionsAUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functionsMedicoseAcademics
 
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdfPAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdfDolisha Warbi
 
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdfSGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdfHongBiThi1
 
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdfSGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdfHongBiThi1
 
Neurological history taking (2024) .
Neurological  history  taking  (2024)  .Neurological  history  taking  (2024)  .
Neurological history taking (2024) .Mohamed Rizk Khodair
 
Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024EwoutSteyerberg1
 
Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024Peter Embi
 
Physiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxationPhysiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxationMedicoseAcademics
 
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.aarjukhadka22
 
"Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio..."Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio...Sujoy Dasgupta
 
historyofpsychiatryinindia. Senthil Thirusangu
historyofpsychiatryinindia. Senthil Thirusanguhistoryofpsychiatryinindia. Senthil Thirusangu
historyofpsychiatryinindia. Senthil Thirusangu Medical University
 
AORTIC DISSECTION and management of aortic dissection
AORTIC DISSECTION and management of aortic dissectionAORTIC DISSECTION and management of aortic dissection
AORTIC DISSECTION and management of aortic dissectiondrhanifmohdali
 
ayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologypptayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologypptPradnya Wadekar
 
Female Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before PregnancyFemale Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before PregnancyMedicoseAcademics
 

Recently uploaded (20)

Adenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosisAdenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosis
 
Using Data Visualization in Public Health Communications
Using Data Visualization in Public Health CommunicationsUsing Data Visualization in Public Health Communications
Using Data Visualization in Public Health Communications
 
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdfSGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
 
CPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing studentCPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing student
 
AUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functionsAUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functions
 
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdfPAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
 
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdfSGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
 
GOUT UPDATE AHMED YEHIA 2024, case based approach with application of the lat...
GOUT UPDATE AHMED YEHIA 2024, case based approach with application of the lat...GOUT UPDATE AHMED YEHIA 2024, case based approach with application of the lat...
GOUT UPDATE AHMED YEHIA 2024, case based approach with application of the lat...
 
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdfSGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
 
Neurological history taking (2024) .
Neurological  history  taking  (2024)  .Neurological  history  taking  (2024)  .
Neurological history taking (2024) .
 
Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024
 
Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024
 
Immune labs basics part 1 acute phase reactants ESR, CRP Ahmed Yehia Ismaeel,...
Immune labs basics part 1 acute phase reactants ESR, CRP Ahmed Yehia Ismaeel,...Immune labs basics part 1 acute phase reactants ESR, CRP Ahmed Yehia Ismaeel,...
Immune labs basics part 1 acute phase reactants ESR, CRP Ahmed Yehia Ismaeel,...
 
Physiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxationPhysiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxation
 
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
 
"Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio..."Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio...
 
historyofpsychiatryinindia. Senthil Thirusangu
historyofpsychiatryinindia. Senthil Thirusanguhistoryofpsychiatryinindia. Senthil Thirusangu
historyofpsychiatryinindia. Senthil Thirusangu
 
AORTIC DISSECTION and management of aortic dissection
AORTIC DISSECTION and management of aortic dissectionAORTIC DISSECTION and management of aortic dissection
AORTIC DISSECTION and management of aortic dissection
 
ayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologypptayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologyppt
 
Female Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before PregnancyFemale Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before Pregnancy
 

2016 BDSRA Fietz, Giugliani, AlSayed, Burke, Cohen-Pfeffer, Cooper, de Halec, Dvorakova, Izzo, Jahnova, Lukacs, Mole, Pearce, Schulz, Specchio, Xin, Miller

  • 1. Expert Recommendations for the Laboratory Diagnosis of Neuronal Ceroid Lipofuscinosis Type 2 (CLN2 disease): Diagnostic Algorithm and Best Practice Guidelines for a Timely Diagnosis Michael Fietz1* , Roberto Giugliani2* , Moeenaldeen AlSayed3 , Derek Burke4 , Jessica Cohen-Pfeffer5 , Jonathan D Cooper6 , Ines Noher de Halac7 , Lenka Dvořáková8 , Emanuela Izzo5 , Helena Jahnová8 , Zoltan Lukacs9 , Sara E. Mole10 , David A. Pearce11 , Angela Schulz12 , Nicola Specchio13 , Winnie Xin14 , and Nicole Miller5 * Co- first authors 1 Department of Diagnostic Genomics, PathWest Laboratory Medicine WA, Nedlands, Australia, 2 Serviço de Genética Médica Hospital de Clinicas de Porto Alegre, Departamento de Genética Universidade Federal do Rio Grande do Sul and National Institute of Medical Genetics Population, Porto Alegre, Rio Grande do Sul, Brazil, 3 Department of Medical Genetics, Alfaisal University and King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia, 4 Chemical Pathology, Camelia Botnar Laboratories, Great Ormond Street Hospital, London, UK, 5 BioMarin Pharmaceutical Inc., Novato, California, USA, 6 Institute of Psychiatry, Psychology, & Neuroscience, King’s College London, London, UK, 7 Facultad de Ciencias Médicas, Universidad Nacional de Córdoba, Córdoba, Argentina and National Research Council-CONICET, Argentina, 8 Institute of Inherited Metabolic Disorders, First Faculty of Medicine, Charles University in Prague and General University Hospital in Prague, Prague, Czech Republic, 9 Newborn screening and Metabolic Diagnostics unit, Hamburg University Medical Center, Hamburg, Germany, 10 MRC Laboratory for Molecular Cell Biology and UCL Institute of Child Health, University College London, London, UK, 11 Sanford Children’s Health Research Center, Sioux Falls, South Dakota, USA, 12 Children’s Hospital, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, 13 Department of Neuroscience, Bambino Gesù Children’s Hospital, Rome, Italy, 14Neurogenetics DNA Diagnostic Lab, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA ABSTRACT The neuronal ceroid lipofuscinoses (NCLs) are a heterogeneous group of lysosomal storage disorders that include the rare autosomal recessive neurodegenerative disorder, CLN2 disease. CLN2 disease is caused by mutations in the TPP1/CLN2 gene, resulting in tripeptidyl peptidase-1 (TPP1) enzyme deficiency. Classic late-infantile CLN2 disease phenotype has a pediatric onset with initial symptoms of language delay and seizures, followed by progressive dementia, motor and visual deterioration, and early death. Variant phenotypes of CLN2 disease occur more rarely. Diagnosis of CLN2 disease is based on laboratory testing following clinical suspicion; however, delays in diagnosis are common due to low disease awareness, non-specific initial symptoms, and limited diagnostic testing access in some regions. With the advent of new therapies, early CLN2 disease diagnosis is key to ensure optimal clinical care and outcomes. In May 2015, a panel of international experts met to recommend best laboratory practices for early diagnosis of CLN2 disease. When NCL is suspected due to the presence of suggestive clinical signs, a TPP1 enzyme activity test should be the first diagnostic test performed (along with palmitoyl protein thioesterase [PPT1] enzyme to exclude CLN1). However, since initial suspicion of CLN2 disease and NCLs is often challenging, where available, the use of epilepsy gene panels for the investigation of unexplained seizures in childhood is endorsed. These panels should include TPP1/CLN2 as well as genes for NCLs that lack diagnostic biochemical tests. Diagnostic TPP1 enzyme testing in leucocytes is well established and robust and in DBS is considered diagnostic if followed by molecular confirmatory testing. Future methods to measure TPP1 activity via tandem mass spectrometry may improve DBS-based TPP1 enzyme testing sensitivity. Experts recommend that to confirm specific clinical suspicion of CLN2 disease, the gold standard for laboratory diagnosis is demonstrating deficient TPP1 enzyme activity and/or detecting causative mutations in each allele of the TPP1/CLN2 gene. Addendum: After abstract submission, the gold standard statement was revised to the following to reflect a more clear recommendation for laboratory diagnosis: “The gold standard for laboratory diagnosis is demonstrating deficient TPP1 enzyme activity and detecting causative mutations in each allele of the TPP1/CLN2 gene.” BACKGROUND ■■ Since early symptoms of CLN2 disease are not specific, prior to ordering specific laboratory tests for diagnosis of CLN2 disease, there are 3 (often sequential) phases through which many clinicians will pass: (1) suspicion of an unknown neurological disorder, (2) general suspicion of an NCL disorder, and finally, (3) specific suspicion of CLN2 disease. –– Diagnosis of CLN2 often involves lengthy diagnostic odysseys (Figure 1). Figure 1. Typical CLN2 Disease Diagnostic Odyssey 1- to 4-year delay Further symptom progression: seizures, language loss, developmental milestone loss, visual deterioration, others Symptoms progress: eizures, motor symptoms, developmental milestone regression, others Early symptoms: unexplained new onset seizures Clinical observations Onset of symptoms Specific confirmatory lab tests: TPP1 enzyme activity defect and gene mutations Diagnostic investigations: clinical tests, generic EEG, MRI, etc Epilepsy or developmental delay gene panels NCL gene panels, enzyme activity or electron microscopy EEG photic stimulation - s panels, light TPP1/CLN2 Unknown neurological disorder Is it linked to a genetic disorder? Clinical/laboratory tests Low suspicion High suspicion CLN2 disease Neuronal ceroid lipofuscinosis The above is a description of typical diagnostic practice. The specific tests ordered, approaches and techniques may vary among different laboratories, clinicians and centers worldwide depending on local diagnostic testing availability and disease awareness. Figure 2. Typical Delays in the Diagnosis of CLN2 Disease Results from survey of NCL clinical experts (N = 12) responding to the question, From your own experience, for patients not initially seen by NCL specialists, what is the time from onset of CLN2 disease symptoms until: 0 10 20 30 40 50 Months from onset of CLN2 symptoms until: 1 year: 82% 1 year: 100% From left to right: minimum, mean, maximum Referral to an NCL specialist Diagnosis with CLN2 disease ■■ Delays in CLN2 disease diagnosis are common, but diagnosis is rapid once patients are referred to appropriate specialists. METHODS ■■ International NCL experts met in May 2015 to discuss and recommend best laboratory practices to support early diagnosis of CLN2 disease. ■■ The algorithms and recommendations here reflect the consensus of the experts. ■■ TPP1 enzyme activities are reported as observed by individual diagnostic laboratories in samples from unaffected individuals, heterozygous carriers, and individuals with CLN2 disease. Laboratories utilized modifications of the fluorogenic TPP1 assay.1-6 The data presented here are not generated from BioMarin-sponsored clinical trial patient samples. APPROACH TO SUSPICION AND DIAGNOSIS ■■ Any unexplained seizure in a child 1 to 9 years of age,7 particularly when associated with a history of language delay and/or developmental milestone regression, should be suspected as linked to a genetic disorder or to an NCL disorder. –– Atypical forms with alternative presentations exist, eg, juvenile forms and autosomal recessive spinocerebellar ataxia 7 (SCAR7 disease, also caused by mutations in the TPP1/CLN2 gene).8 ■■ When a genetic neurological disorder is suspected, a molecular gene panel test to investigate genetic causes of childhood-onset epilepsy or developmental delay is recommended. –– Experts recommend that the TPP1/CLN2 gene should be included in such gene panels. ■■ When NCL disorders in general are suspected, targeted NCL gene panels may help in reaching a diagnosis of CLN2 disease, as well as other types of NCLs. ■■ EEG analysis under specific intermittent photic stimulation (1 to 2 Hz) may be of use as a clinical test to reach a suspicion of CLN2 disease.9-11 –– EEG spikes in the posterior region in response to photic stimulation at 1-2 Hz are characteristic of CLN2 disease and some other late-infantile NCLs (eg, CLN6 and CLN8 diseases). ■■ Early testing of TPP1 and PPT1 enzyme deficiency can rapidly rule out or confirm suspicion of CLN2 or CLN1 disease, respectively. –– Assays for TPP1 and PPT1 enzyme activity are widely available. –– CLN2 and CLN1 disease are the most prevalent NCL disorders among the late infantile NCL types.10 –– Enzyme activity assay exists also for cathepsin D (CLN10 disease), but routine laboratory testing for this enzyme is currently less common. Figure 3. Algorithm for Suspicion and Diagnosis of CLN2 Disease Suspicion of a genetic disorder Suspicion of an NCL disorder Observation of common initial symptoms at late-infantile age (2 to 4 years; classic phenotype) or at juvenile age (> 4 years; atypical phenotype): • New-onset seizures, in association with • A history of language delay and/or developmental milestone regression Intermittent photic stimulation (1 to 2 Hz) or screening of TPP1 and PPT1 enzymesa Disease or symptom gene panelb or screening of TPP1 and PPT1 enzymesa NCL gene panelb or screening of TPP1 and PPT1 enzymesa TPP1 enzyme activity analysis Leukocytes or fibroblasts or DBSc Molecular analysis of the TPP1/CLN2 geneb Diagnosis Suspicion Clinical testing and differential diagnosis Suspicion of CLN2 disease Laboratory confirmatory diagnosis of CLN2 disease CLN2 disease diagnosis DBS, dried blood spot. a Early screening of TPP1 and PPT1 deficiency (eg, in DBS) can rule out or confirm CLN2 suspicion. b Molecular testing alone may be diagnostic if 2 pathogenic mutations consistent with clinical presentation are detected in trans. c A finding of deficient TPP1 enzyme activity in leukocytes or fibroblasts may be considered diagnostic if consistent with clinical presentation, but molecular analysis is recommended. ■■ Following clinical suspicion, diagnosis of CLN2 disease is based on specific well-established laboratory tests. ■■ TPP1 enzyme activity can be assessed in several sample types. ■■ Molecular analysis of the TPP1/CLN2 gene can confirm a diagnosis and assist genetic counseling. The gold standard for diagnosis of CLN2 disease is: ■■ Demonstration of decreased or deficient TPP1 enzyme activity (together with normal activity of appropriate controls); and ■■ Detection of 1 deleterious mutation in each allele of the TPP1/CLN2 gene ■■ If it is not possible to perform both the TPP1 enzyme assay and molecular testing due to local restrictions: –– A finding of deficient TPP1 enzyme activity in leukocytes or fibroblasts is diagnostic when consistent with the clinical presentation of CLN2 disease. –– Detection of two pathogenic TPP1/CLN2 mutations in trans is diagnostic in the absence of TPP1 enzyme testing results when consistent with clinical presentation. RECOMMENDATIONS FOR LABORATORY DIAGNOSIS Analysis of TPP1 Enzyme Activity ■■ The TPP1 enzyme is a lysosomal exopeptidase that cleaves N-terminal tripeptides.1-3,12 ■■ Diagnostic laboratory assessment of TPP1 enzyme activity utilizes the fluorogenic substrate Ala-Ala-Phe-7-amido-4-methylcoumarin.2,3,12 –– A substrate for assessment of TPP1 enzyme activity by tandem mass spectrometry has been developed13 and may support future screening of newborn DBS samples. 143 ■■ Several variants on the fluorogenic TPP1 enzyme assay have been published.4-6 ■■ It is essential to assay the activity of control enzymes. –– PPT1 (mutated in CLN1 disease) and β-galactosidase are appropriate control enzymes. Figure 4. TPP1 Enzyme Activity in Leukocyte Samples, by Diagnostic Laboratory 1 2 3 4 5 0 100 200 Patient with CLN2 disease Laboratory TPP1 Enzyme Activity, nmol/h/mg protein Carrier Unaffected individuals 300 400 ■■ Different assay implementations can distinguish affected from unaffected individuals. –– Laboratories must establish reference ranges for their individual implementation. Molecular Analysis of the TPP1/CLN2 Gene ■■ Mutations have been reported throughout the TPP1/CLN2 gene.14 ■■ Two deleterious mutations are frequently reported: c.509-1GC and c.622CT (p.Arg208*). –– These two mutations together represent 57% of all reported mutations. –– At least 1 of these 2 mutations is reported in 89% of patients with CLN2 disease.14 ■■ Sequencing should evaluate the entire coding region and associated splice junctions. ■■ A database of mutations associated with the TPP1/CLN2 gene, and other NCL genes, is maintained at http://www.ucl.ac.uk/ncl/mutation. Figure 5. Reported Frequency of TPP1/CLN2 Mutant Alleles14 c.509-1GC 156 p.Arg208* 149 At least 1 reported in 89% of patients Missense Splice site Nonsense/stop p.Gly284Val p.Gln509* p.Gln422His 35 18 10 176 0 25 50 75 100 Mutation Reported in Kousi et al, 2012 125 150 175 200 84 mutations reported 10 times CONCLUSIONS ■■ CLN2 disease is a rare, progressive, and devastating disease that can be difficult to identify clinically at an early stage. –– Key initial symptoms in many patients are new-onset seizures, often in combination with a history of early language delay. –– Atypical forms of disease—with alternative presentations—caused by mutations in the TPP1/CLN2 gene also exist, such as SCAR7.8 ■■ Delays in diagnosis are common due to the time necessary to come to suspicion of CLN2 disease. Valuable tools to help speed time to diagnosis include: –– EEG intermittent photic stimulation (1 to 2 Hz). –– Symptom- or disease-based gene panels that include the TPP1/CLN2 gene. –– Early screening for TPP1 enzyme deficiency (together with PPT1 for CLN1). ■■ Diagnostic laboratory testing for CLN2 disease is well established. ■■ The gold standard for laboratory diagnosis is demonstration of deficient TPP1 enzyme activity and molecular analysis that detects 1 pathogenic mutation on each allele of TPP1/CLN2 gene. REFERENCES 1. Sohar I, et al. J Neurochem. 1999;73:700-711. 2. Vines D, Warburton MJ. Biochim Biophys Acta. 1998;1384:233-242. 3. Vines D, Warburton MJ. FEBS Lett. 1999;443:131-135. 4. Muller VJ, et al. Eur J Paediatr Neurol. 2001;5(suppl A):197-200. 5. Young EP, et al. Prenat Diagn. 2000;20:337-339. 6. Van Diggelen OP et al. Eur J Paediatr Neurol. 2001;5(suppl A):189-200. 7. Kohan R et al. Biochim Biophys Acta. 2013;1852:2301-2311. 8. Sun Y et al. Hum Mutat. 2013;34:706-713. 9. Binelli S, et al. Neurol Sci. 2000;21:S83-S87. 10. Mole SE, et al. The Neuronal Ceroid Lipofuscinoses (Batten disease). 2nd edition. Oxford, UK: Oxford University Press; 2011. 11. Naqvi SZ, et al. Pediatr Neurol. 1998;19:395-398. 12. Sleat DE, et al. Science. 1997;277:1802-1805. 13. Barcenas M, et al. Anal Chem. 2014;86:7962-7968. 14. Kousi M, et al. Hum Mutat. 2012;33:42-63. ACKNOWLEDGMENTS The authors thank Karl Zawadzki, PhD, and Evelyn Rose, PharmD (Health Interactions), for assistance with the preparation of this poster, which was funded by BioMarin Pharmaceutical Inc. ©2016 BioMarin Pharmaceutical Inc. All rights reserved.Presented at the 12th Annual WORLD Symposium: 29 February – 4 March, 2016, San Diego, CA http://www.biomarin.com/pdf/WORLD2016p7.pdf